Scientists at the University of Birmingham have discovered that gut bacteria and their associated chemical compounds, known as metabolites, act as biological markers for serious digestive diseases. By applying artificial intelligence to clinical data, the team identified patterns that could lead to faster, less invasive diagnostic methods for gastric cancer, colorectal cancer, and inflammatory bowel disease (IBD).
The study, published in the Journal of Translational Medicine, utilized machine learning to analyze the microbiome and metabolome of patients. Researchers found that models trained on data from one gastrointestinal condition could often predict markers for others, suggesting these diseases share fundamental biological pathways.
AI uncovers shared disease markers
Lead co-author Dr. Animesh Acharjee said the current reliance on endoscopies and biopsies can be both expensive and invasive, often missing diseases in their early stages. "Our analysis offers a better understanding of the underlying mechanisms driving disease progression and identifies key biomarkers for targeted therapies," he stated.
The researchers identified distinct bacterial clusters for various conditions. For instance, gastric cancer cases showed high levels of Firmicutes and Bacteroidetes, while colorectal cancer was linked to the presence of Fusobacterium and Enterococcus. IBD was characterized by specific changes in the Lachnospiraceae family and metabolites like urobilin.
While some signatures were disease-specific, the researchers found significant overlap. Certain metabolites involved in gut inflammation also appeared in cancer-related processes. These simulations of how microbes grow and move through the body revealed clear metabolic differences between healthy individuals and those suffering from gastrointestinal disease.
Looking ahead, the team plans to validate these findings with larger, more diverse patient groups. The goal is to develop universal diagnostic tools that can identify multiple conditions from a single set of non-invasive tests, potentially revolutionizing how gastrointestinal health is monitored and treated.
The research was conducted by a team from the University of Birmingham in the UK and Dubai, in collaboration with the University Hospitals Birmingham NHS Foundation Trust.
